Canopy Growth Shares Plunge On CA$1.33B Q4 Loss
That's up from the loss of CA$347.5 million Canopy posted for the same quarter a year ago.
The Smiths Falls, Ontario-based company reported net revenue of CA$399 million for the quarter, up 76% year-over-year and down 13% quarter-over-quarter.
Here's a breakdown of what the earnings report revealed:
- A negative gross margin of 8% for the full year and 85% for the quarter — including one-time restructuring and separate charges — and adjusted gross margins of 26% and 42%, respectively
- Impairment and restructuring charges of CA$743 million
- 17% increase in SG&A expenses during the fourth quarter, compared to the previous period
- Adjusted EBITDA loss of CA$102 million in the fourth quarter and a loss of CA$442 million for fiscal 2020
- Gross cash flow decreased by approximately 13% sequentially, to CA$2 billion in the fourth quarter
- Recreational business-to-business sales fell by 31% sequentially
- Business-to-consumer sales decreased by 14% during the same period
- Medical cannabis sales hovered at CA$14.9 million over the past six months
"I am excited to implement our strategy reset and organization redesign over the course of fiscal 2021," CEO David Klein said in a statement. "We have a renewed strategic focus and a clear change agenda that is already underway."
Despite the global health crisis, the company expanded its product portfolio by launching new cannabis-infused beverages, vape and CBD products in both Canada and the U.S., Klein said.
The company's new approach to the business includes building a presence in select priority markets within the cannabis space and focusing on consumer insights, analytics and product development.
Canopy made operational changes in April. It laid off around 85 full-time employees; quit its operations in South Africa and Lesotho; closed an indoor facility in Yorkton, Saskatchewan; and canceled its farming activities in Springfield, New York.
Canopy Growth shares were down 20.25% at $17.33 at the time of publication Friday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.